Form 4: Bionano Genomics Executive Acquires Shares and Stock Options
SEC Form 4 Filing
Mark Oldakowski, Chief Operating Officer of Bionano Genomics, reports acquisition of shares and stock options.
Summary
- On June 3, 2024, Mark Oldakowski, the Chief Operating Officer of Bionano Genomics, acquired 16,000 shares of common stock and 75,000 stock options.
- The shares were acquired through a restricted stock unit award granted under the company's 2018 Equity Incentive Plan.
- The restricted stock units vest 1/4th annually, starting one year from the grant date.
- The stock options, with an exercise price of $0.93, vest monthly over 48 months, beginning on June 3, 2024, and will be fully vested by the four-year anniversary of the grant date.
- Following these transactions, Oldakowski directly owns 64,698 shares of common stock and 75,000 stock options.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard disclosure of insider transactions. The acquisition of shares and options could be interpreted as a positive sign, but it's not definitive.
Positives
- The acquisition of shares and stock options by a key executive could be seen as a positive sign, indicating confidence in the company's future prospects.
- The vesting schedules for both the restricted stock units and stock options incentivize long-term commitment from the executive.
Future Outlook
The document does not contain specific forward-looking statements, but the vesting schedules suggest a long-term commitment from the executive.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Monitoring such filings can provide insights into management's sentiment and expectations for the company.
Stakeholder Impact
- The transactions could have a minor positive impact on shareholder sentiment if interpreted as a sign of confidence from the COO.
Key Dates
| Date | Description |
|---|---|
| 06/09/2023 | Includes 54 shares acquired under the Issuer's 2018 Employee Stock Purchase Plan (the 'ESPP'). |
| 06/03/2024 | Date of transaction: acquisition of common stock and stock options. |
| 06/03/2024 | Grant Date of stock options, vesting monthly over 48 months. |
| 06/02/2034 | Expiration date of stock options. |
| 06/05/2024 | Date of signature for the Form 4 filing. |
Keywords
Bionano Genomics, Mark Oldakowski, stock options, restricted stock units, Form 4, insider trading, equity incentive plan, common stock
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.